+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Sarcoma Therapeutics Market 2019-2023 - Product Image

Global Sarcoma Therapeutics Market 2019-2023

  • ID: 4721499
  • Report
  • December 2018
  • Region: Global
  • 114 pages
  • TechNavio
UP TO OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Bayer
  • Eisai
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE
The advent of regenerative medicine to drive growth in the market. One of the most advanced and extensively researched treatment methods is regenerative medicines, including gene therapy. In gene therapy, the mutated gene is taken from the patient and is modified genetically in laboratory and administered back into the patient. The analysts have predicted that the sarcoma therapeutics market will register a CAGR of more than 8% by 2023.

Market Overview

Launch of novel drugs

The market is currently dominated by the sales of GLEEVEC for the treatment of sarcomas. The launch of novel drugs is expected to be one of the major growth drivers in the market.

High treatment costs

The cost of therapeutics is usually high as most of the drugs that are currently approved in the market are large molecules. These drugs are expensive due to the complex manufacturing process of biologicals and high R&D costs.

For the detailed list of factors that will drive and challenge the growth of the sarcoma therapeutics market during the 2019-2023, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Bayer and Eisai, the competitive environment is quite intense. Factors such as the advent of regenerative medicine and the launch of novel drugs, will provide considerable growth opportunities to sarcoma therapeutics manufactures. Bayer, Eisai, Eli Lilly, Johnson & Johnson, and Novartis are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bayer
  • Eisai
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY TYPE
  • Market segmentation by type
  • Comparison by type
  • Soft tissue sarcoma - Market size and forecast 2018-2023
  • Osteosarcoma - Market size and forecast 2018-2023
  • Market opportunity by type
PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • Americas - Market size and forecast 2018-2023
  • EMEA - Market size and forecast 2018-2023
  • APAC - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 14: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Bayer
  • Eisai
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
PART 15: APPENDIX
  • Research methodology
  • List of abbreviations
List of Exhibits
Exhibit 01: Global oncology therapeutics market
Exhibit 02: Segments of global oncology therapeutics market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global sarcoma therapeutics market pipeline: Overview
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Soft tissue sarcoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Soft tissue sarcoma - Year-over-year growth 2019-2023 (%)
Exhibit 22: Osteosarcoma - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Osteosarcoma - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: Americas - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: Americas - Year-over-year growth 2019-2023 (%)
Exhibit 30: EMEA - Market size and forecast 2018-2023 ($ millions)
Exhibit 31: EMEA - Year-over-year growth 2019-2023 (%)
Exhibit 32: APAC - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: APAC - Year-over-year growth 2019-2023 (%)
Exhibit 34: Key leading countries
Exhibit 35: Market opportunity
Exhibit 36: Impact of drivers and challenges
Exhibit 37: Vendor landscape
Exhibit 38: Landscape disruption
Exhibit 39: Vendors covered
Exhibit 40: Vendor classification
Exhibit 41: Market positioning of vendors
Exhibit 42: Bayer - Vendor overview
Exhibit 43: Bayer - Business segments
Exhibit 44: Bayer - Organizational developments
Exhibit 45: Bayer - Geographic focus
Exhibit 46: Bayer - Segment focus
Exhibit 47: Bayer - Key offerings
Exhibit 48: Bayer - Key customers
Exhibit 49: Eisai - Vendor overview
Exhibit 50: Eisai - Business segments
Exhibit 51: Eisai - Organizational developments
Exhibit 52: Eisai - Geographic focus
Exhibit 53: Eisai - Segment focus
Exhibit 54: Eisai - Key offerings
Exhibit 55: Eisai - Key customers
Exhibit 56: Eli Lilly - Vendor overview
Exhibit 57: Eli Lilly - Business segments
Exhibit 58: Eli Lilly - Organizational developments
Exhibit 59: Eli Lilly - Geographic focus
Exhibit 60: Eli Lilly - Segment focus
Exhibit 61: Eli Lilly - Key offerings
Exhibit 62: Eli Lilly - Key customers
Exhibit 63: Johnson & Johnson - Vendor overview
Exhibit 64: Johnson & Johnson - Business segments
Exhibit 65: Johnson & Johnson - Organizational developments
Exhibit 66: Johnson & Johnson - Geographic focus
Exhibit 67: Johnson & Johnson - Segment focus
Exhibit 68: Johnson & Johnson - Key offerings
Exhibit 69: Johnson & Johnson - Key customers
Exhibit 70: Novartis - Vendor overview
Exhibit 71: Novartis - Business segments
Exhibit 72: Novartis - Organizational developments
Exhibit 73: Novartis - Geographic focus
Exhibit 74: Novartis - Segment focus
Exhibit 75: Novartis - Key offerings
Exhibit 76: Novartis - Key customers
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Bayer
  • Eisai
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
  • MORE
Global Sarcoma Therapeutics Market 2019-2023

The analyst recognizes the following companies as the key players in the global sarcoma therapeutics market: Bayer, Eisai, Eli Lilly, Johnson & Johnson, and Novartis.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the advent of regenerative medicine.”

According to the report, one of the major drivers for this market is the launch of novel drugs.

Further, the report states that one of the major factors hindering the growth of this market is the high treatment costs.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Bayer
  • Eisai
  • Eli Lilly
  • Johnson & Johnson
  • Novartis
Note: Product cover images may vary from those shown
Adroll
adroll